Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ring-B modified anthracyclines.

A Suarato1, F Angelucci, C Geroni

  • 1Discovery Research Oncology, Pharmacia & Upjohn S.p.A., Viale Pasteur, Nerviano, 10 20014 (MI), Italy.

Current Pharmaceutical Design
|March 6, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The folding and aggregation properties of a single KH-domain protein: Ribosome binding factor A (RbfA) from Pseudomonas aeruginosa.

Biochimica et biophysica acta. General subjects·2020
Same author

YAP/TAZ mechano-transduction as the underlying mechanism of neuronal differentiation induced by reduced graphene oxide.

Nanomedicine (London, England)·2018
Same author

Management della retinopatia diabetica e dell'edema maculare diabetico: linee guida "Euretina 2017".

La Clinica terapeutica·2017
Same author

Infections in hospital departments. What is Hospital Responsibility?

La Clinica terapeutica·2017
Same author

Switching between the alternative structures and functions of a 2-Cys peroxiredoxin, by site-directed mutagenesis.

Journal of molecular biology·2013
Same author

BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia.

European psychiatry : the journal of the Association of European Psychiatrists·2010
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
Same journal

Pharmacological Insights into Medicinal Plants and Phytomolecules for the Management of Alopecia with Mechanistic Perspectives and Therapeutic Potential.

Current pharmaceutical design·2026
Same journal

Addressing Challenges, Regulatory Shifts, and the Need for Cost-Effective Alternatives for Complex Topical Formulations.

Current pharmaceutical design·2026
Same journal

The Mechanism of Huaiqihuang in the Treatment of Nephrotic Syndrome: An Integrated Study Based on Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation.

Current pharmaceutical design·2026
Same journal

Resveratrol and the NLRP3 Inflammasome: Unlocking the Anti-inflammatory Potential of a Natural Compound.

Current pharmaceutical design·2026
Same journal

The Use of Hemostatic Agents in Traumatic Bleeding: One Size Does Not Fit All.

Current pharmaceutical design·2026
See all related articles

Researchers explored novel anthracycline analogues to improve antitumor drug effectiveness and reduce toxicity. Modifications to the aglycone moiety showed promising activity but not against multidrug-resistant (MDR) tumors, while sugar modifications enhanced MDR activity.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Organic Synthesis

Background:

  • Anthracyclines are a key class of antitumor drugs, with ongoing efforts to synthesize analogues with improved efficacy and reduced toxicity.
  • Previous studies indicate that structural modifications can lead to reduced cardiotoxicity and activity against multidrug resistance (MDR).
  • 4-demethoxydaunorubicin demonstrated superior potency and reduced cardiotoxicity compared to daunorubicin, motivating further exploration of anthracycline analogues.

Purpose of the Study:

  • To synthesize and evaluate novel anthracycline analogues with modified substitution patterns on the anthraquinone system, specifically ring-B.
  • To assess the antitumor activity and effects on MDR tumors of these new derivatives.
  • To investigate the structure-activity relationships concerning cardiotoxicity and MDR activity.

Related Experiment Videos

Main Methods:

  • Total synthesis of three classes of anthracycline derivatives with alterations in ring-B (hydroxyl removal, replacement with nitro or amino groups).
  • Evaluation of the antitumor activity of synthesized analogues.
  • Assessment of the activity of these analogues against multidrug-resistant (MDR) tumors.
  • Introduction of a morpholino group in the sugar moiety of selected analogues to study its impact on MDR activity.

Main Results:

  • Modifications to ring-B of the anthracycline structure resulted in compounds with promising pharmacological activity.
  • These ring-B modifications did not significantly alter the activity against multidrug-resistant (MDR) tumors.
  • The introduction of a morpholino group in the sugar portion of the anthracycline analogues dramatically increased activity against MDR tumors.

Conclusions:

  • Activity against multidrug-resistant (MDR) tumors in anthracyclines is not solely dependent on modifications within the aglycone moiety.
  • Sugar-moiety modifications, such as the introduction of a morpholino group, play a crucial role in enhancing activity against MDR tumors.
  • Further research into sugar modifications could lead to more effective anthracycline-based therapies for MDR cancers.